ABEO logo

ABEONA THERAPEUTICS INC

ABEONASDAQ
🏆 #3409 by market capEarnings Nov 16US Equity
$4.55▲ $0.08 (+1.79%)
Pre-market · at close
🔔
Track ABEO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.8%
7d▲ 2.0%
14d▼ 2.3%
30d▼ 11.8%
ytd▼ 13.7%
1y▼ 9.0%
🏦Market Cap
$260M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
56.6%
Healthy
💵FCF Margin
-319.5%
Thin
⚖️P/S Ratio
10.0x
Elevated
Otter Score
52
Fair

Trading Snapshot

Day Range
$4.45 – $4.58
52-Week Range
$4.00 – $7.65
Volume (shares)
41,591
Avg Volume (shares)
—
Shares Outstanding
57.2M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$11M
P/E Ratio
-3.9
P/S Ratio
10.0x
EPS (TTM)
$-1.10
Dividend Yield
0.00%
Dilution (1yr)
+61.1%
ABEO logo

ABEONA THERAPEUTICS INC

ABEO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
73.7%▲ +36.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$89M▲ +39.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$84M▲ +44.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
66.1M▲ +61.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$53M▲ +$53M YoY
StockOtter · stockotter.space

About ABEONA THERAPEUTICS INC

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
52/100
Analyst data unavailable.

Latest News & Updates

News unavailable.